Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28(Suppl 1):68–76.
Zhang H, Chen L, Xin Y, Lou Y, Liu Y, Xuan S. Apolipoprotein c3 gene polymorphisms are not a risk factor for developing non-alcoholic Fatty liver disease: a meta-analysis. Hepatmon. 2014;14(10):e23100.
Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, et al. Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85.
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. [Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update]. Zhonghua Gan Zang Bing Za Zhi. 2018;26(3):195–203. Chinese. https://doi.org/10.3760/cma.j.issn.1007-3418.2018.03.008.
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.
Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64–76.
Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41(2):372–82.
Zheng X, Cao C, He Y, Wang X, Wu J, Hu H. Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. Lipids Health Dis. 2021;20(1):59.
Zhang M, Lin S, Wang MF, Huang JF, Liu SY, Wu SM, Zhang HY, Wu ZM, Liu WY, Zhang DC, et al. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? Bmc Gastroenterol. 2020;20(1):139.
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.
Jiang T, Chen X, Xia C, Liu H, Yan H, Wang G, Wu Z. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study. Sci Rep. 2019;9(1):4874.
Mikolasevic I, Milic S, Turk WT, Grgic I, Jakopcic I, Stimac D, Wensveen F, Orlic L. Nonalcoholic fatty liver disease – A multisystem disease? World J Gastroenterol. 2016;22(43):9488–505.
Yang MH, Sung J, Gwak GY. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016;10(2):289–98.
Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46(2):85–95.
Sporea I, Popescu A, Dumitrașcu D, Brisc C, Nedelcu L, Trifan A, Gheorghe L, Fierbințeanu BC. Nonalcoholic fatty liver disease: status quo. J Gastrointest Liver Dis. 2018;27(4):439–48.
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82–97.
Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine. 2012;91(6):319–27.
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–73.
VanWagner LB, Armstrong MJ. Lean NAFLD: a not so benign condition? Hepatol Commun. 2018;2(1):5–8.
Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2018;2(1):48–57.
Fukuda T, Hamaguchi M, Kojima T, Hashimoto Y, Ohbora A, Kato T, Nakamura N, Fukui M. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. LIVER INT. 2016;36(2):275–83.
Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, Yang MJ, Lim SG, Kim S, Cheong JY, et al. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis. 2018;50(4):370–7.
Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study. Medicine. 2017;96(18): e6712.
Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.
Imajo K, Hyogo H, Yoneda M, Honda Y, Kessoku T, Tomeno W, Ogawa Y, Taguri M, Mawatari H, Nozaki Y, et al. LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study. PLoS ONE. 2014;9(12): e115403.
Sun DQ, Wu SJ, Liu WY, Wang LR, Chen YR, Zhang DC, Braddock M, Shi KQ, Song D, Zheng MH. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ Open. 2016;6(12): e13781.
Sun DQ, Liu WY, Wu SJ, Zhu GQ, Braddock M, Zhang DC, Shi KQ, Song D, Zheng MH. Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. Oncotarget. 2016;7(5):5728–37.
Li JJ, Huang YH, Lin YY, Li MM, Chen YF, Cai RW. The association of uric acid with leukoaraiosis. J Int Med Res. 2017;45(1):75–81.
Xu X, Li C, Zhou P, Jiang T. Uric acid transporters hiding in the intestine. Pharm Biol. 2016;54(12):3151–5.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.
Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Med Indones. 2017;49(2):136–47.
Al-Daghri NM, Al-Attas OS, Wani K, Sabico S, Alokail MS. Serum uric acid to creatinine ratio and risk of metabolic syndrome in Saudi type 2 diabetic patients. Sci Rep. 2017;7(1):12104.
Gu L, Huang L, Wu H, Lou Q, Bian R. Serum uric acid to creatinine ratio: a predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function. Diab Vasc Dis Res. 2017;14(3):221–5.
Durmus KN, Sasak G, Aka AU, Akgun M, Boga S, Sengul A, Gungor S, Arinc S. Serum uric acid levels and uric acid/creatinine ratios in stable chronic obstructive pulmonary disease (COPD) patients: are these parameters efficient predictors of patients at risk for exacerbation and/or severity of disease? Med Sci Monit. 2016;22:4169–76.
Seo YB, Han AL. Association of the serum uric acid-to-creatinine ratio with nonalcoholic fatty liver disease diagnosed by computed tomography. Metab Syndr Relat Disord. 2021;19(2):70–5.
Ma C, Liu Y, He S, Zeng J, Li P, Ma C, Ping F, Zhang H, Xu L, Li W, et al. C-Peptide: a mediator of the association between serum uric acid to creatinine ratio and non-alcoholic fatty liver disease in a chinese population with normal serum uric acid levels. Front Endocrinol. 2020;11:600472.
Zhang N, Hu X, Zhang Q, Bai P, Cai M, Zeng TS, Zhang JY, Tian SH, Min J, Huang HT, et al. Non-high-density lipoprotein cholesterol: high-density lipoprotein cholesterol ratio is an independent risk factor for diabetes mellitus: Results from a population-based cohort study. J Diabetes. 2018;10(9):708–14.
Steventon JJ, Trueman RC, Ma D, Yhnell E, Bayram-Weston Z, Modat M, Cardoso J, Ourselin S, Lythgoe M, Stewart A, et al. Longitudinal in vivo MRI in a Huntington’s disease mouse model: Global atrophy in the absence of white matter microstructural damage. Sci Rep. 2016;6:32423.
Zeng MD, Li YM, Chen CW, Lu LG, Fan JG, Wang BY, Mao YM. Guidelines for the diagnosis and treatment of alcoholic liver disease. J Dig Dis. 2008;9(2):113–6.
Wang J, Xie P, Huang JM, Qu Y, Zhang F, Wei LG, Fu P, Huang XJ. The new Asian modified CKD-EPI equation leads to more accurate GFR estimation in Chinese patients with CKD. Int Urol Nephrol. 2016;48(12):2077–81.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.
Shamu T, Chimbetete C, Egger M, Mudzviti T. Treatment outcomes in HIV infected patients older than 50 years attending an HIV clinic in Harare, Zimbabwe: a cohort study. PLoS ONE. 2021;16(6): e253000.
Ding Q, Xu L, Zhu Y, Xu B, Chen X, Duan Y, Xie Z, Shen K. Comparison of clinical features of acute lower respiratory tract infections in infants with RSV/HRV infection, and incidences of subsequent wheezing or asthma in childhood. BMC Infect Dis. 2020;20(1):387.
Rifkin DE, Katz R, Chonchol M, Fried LF, Cao J, de Boer IH, Siscovick DS, Shlipak MG, Sarnak MJ. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant. 2010;25(5):1560–7.
Wu SJ, Zou H, Zhu GQ, Wang LR, Zhang Q, Shi KQ, Han JB, Huang WJ, Braddock M, Chen YP, et al. Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver disease. Medicine. 2015;94(19): e842.
Wu SJ, Zhu GQ, Ye BZ, Kong FQ, Zheng ZX, Zou H, Shi KQ, Lin L, Braddock M, Huang WJ, et al. Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. Medicine. 2015;94(17): e802.
Groenwold RH, White IR, Donders AR, Carpenter JR, Altman DG, Moons KG. Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis. CMAJ. 2012;184(11):1265–9.
White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377–99.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.
Rothenbacher D, Rehm M, Iacoviello L, Costanzo S, Tunstall-Pedoe H, Belch J, Söderberg S, Hultdin J, Salomaa V, Jousilahti P, et al. Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project. BMC Med. 2020;18(1):300.
Wu L, Zhang M, Hu H, Wan Q. Elevated gamma-glutamyl transferase has a non-linear association with incident non-alcoholic fatty liver disease in the non-obese Chinese population: a secondary retrospective study. Lipids Health Dis. 2021;20(1):142.
Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H, Fagherazzi G, Mancini FR, Boutron-Ruault MC, Kühn T, et al. Association between soft drink consumption and mortality in 10 European Countries. JAMA Intern Med. 2019;179(11):1479–90.
Keidel D, Anto JM, Basagaña X, Bono R, Burte E, Carsin AE, Forsberg B, Fuertes E, Galobardes B, Heinrich J et al. the role of socioeconomic status in the association of lung function and air pollution-a pooled analysis of three adult escape cohorts. Int J Environ Res Public Health 2019; 16(11).
Sun D, Li W, Zhang H, Li Y, Zhang Q. Inverted U-shaped relationship between body mass index and multivessel lesions in Chinese patients with myocardial infarction: a cross-sectional study. J Int Med Res. 2020;48(7):1220732372.
Vesa CM, Behl T, Nemeth S, Bratu OG, Diaconu CC, Moleriu RD, Negrut N, Zaha DC, Bustea C, Radu FI, et al. Prediction of NAFLD occurrence in prediabetes patients. Exp Ther Med. 2020;20(6):190.
Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol. 2020;26(44):7046–60.
Zhu F, Chen C, Zhang Y, Chen S, Huang X, Li J, Wang Y, Liu X, Deng G, Gao J. Elevated blood mercury level has a non-linear association with infertility in U.S. women: data from the NHANES 2013–2016. Reprod Toxicol. 2020;91:53–8.
Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321(6):602–3.
Zhou M, Yang N, Xing X, Chang D, Li J, Deng J, Chen Y, Hu C, Zhang R, Lu X, et al. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMC Gastroenterol. 2021;21(1):43.
Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. AM J Gastroenterol. 2013;108(8):1299–304.
Wang J, Zhang Y, Liu Z, Yang Y, Zhong Y, Ning X, Zhang Y, Zhao T, Xia L, Geng F, et al. Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms. BMC Psychiatry. 2020;20(1):410.
Ge P, Yang H, Lu J, Liao W, Du S, Xu Y, Xu H, Zhao H, Lu X, Sang X, et al. Albumin binding function: the potential earliest indicator for liver function damage. Gastroenterol Res Pract. 2016;2016:5120760.
Tian J, Zhong R, Liu C, Tang Y, Gong J, Chang J, Lou J, Ke J, Li J, Zhang Y, et al. Association between bilirubin and risk of non-alcoholic fatty liver disease based on a prospective cohort study. Sci Rep. 2016;6:31006.
Akhavan RA, Dadgar MM, Ghasemi NM, Shirazinia M, Ghodsi H, Rouhbakhsh ZM, Tavakolizadeh NM, Hoseini B, Akhavan RK. Association between smoking and non-alcoholic fatty liver disease: a systematic review and meta-analysis. SAGE Open Med. 2018;6:2104817223.
Noureddin M, Loomba R. Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis. 2012;1(4):104–7.
Amor AJ, Perea V. Dyslipidemia in nonalcoholic fatty liver disease. Curr Opin Endocrinol Diabetes Obes. 2019;26(2):103–8.
Shih MH, Lazo M, Liu SH, Bonekamp S, Hernaez R, Clark JM. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc. 2015;114(4):314–20.
Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, Zhang Z, Yang Z. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 2015;100(11):4198–207.
Lin KM, Lu CL, Hung KC, Wu PC, Pan CF, Wu CJ, Syu RS, Chen JS, Hsiao PJ, Lu KC. The paradoxical role of uric acid in osteoporosis. Nutrients. 2019;11(9):2111.
Spahis S, Delvin E, Borys JM, Levy E. Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal. 2017;26(10):519–41.
Jian C, Xu Y, Ma X, Shen Y, Wang Y, Bao Y. Neck circumference is an effective supplement for nonalcoholic fatty liver disease screening in a community-based population. Int J Endocrinol. 2020;2020:7982107.
Alsabaani AA, Mahfouz AA, Awadalla NJ, Musa MJ, Al HS. Non-alcoholic fatty liver disease among type-2 diabetes mellitus patients in Abha City, South Western Saudi Arabia. Int J Environ Res Public Health. 2018;15(11):2521.
Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, Gao Z, Yu X. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol. 2012;12:123.
Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol. 2014;20(26):8377–92.